Pregnant Hemophilia B Carriers Have Three Times the Risk of Postpartum Hemorrhage, Swedish Study Finds

Pregnant Hemophilia B Carriers Have Three Times the Risk of Postpartum Hemorrhage, Swedish Study Finds

Pregnant women who are hemophilia B carriers have more than three times the risk of bleeding following childbirth than non-carriers, a register-based study done in Sweden has found.

In contrast, researchers found no differences in the risk of postpartum bleeding between hemophilia A carriers and non-carriers, or in the risk of complications during pregnancy or in the newborn — such as preeclampsia, preterm birth, or low birth weight — between hemophilia carriers and healthy women.

The study, “Maternal and neonatal outcomes in carriers of haemophilia A and B: A Swedish Medical Birth Register study,” was published in the journal Haemophilia.

Pregnancy influences the levels of blood clotting factors. In healthy women, the activity of factor VIII (FVIII) — the missing coagulation factor in hemophilia A — more than doubles in the third trimester and drops back to normal levels within days following delivery. Conversely, factor IX (FIX) activity — the clotting factor defective in hemophilia B — increases slightly or remains the same during normal pregnancy.

In female carriers of hemophilia A, who have a deficiency in FVIII, the activity of this clotting factor can also increase significantly during pregnancy and reach normal levels in most cases.

For hemophilia B carriers, however, FIX levels do not rise significantly and remain low during pregnancy.

Although most carriers have normal pregnancies without any bleeding complications, factor levels should be tested in the third trimester of pregnancy when they are at their highest.

If clotting factors are too low, guidelines recommend preventive replacement therapy (FVIII or IX concentrate) to reduce the risk of excessive bleeding during labor.

In this study, researchers wanted to determine the risk of bleeding among pregnant hemophilia A and B carriers under routine clinical practice in Sweden. They also wanted to evaluate the rate of maternal and neonatal complications.

Therefore, they retrospectively analyzed data from 298 pregnancies in 153 hemophilia A carriers, and 51 pregnancies in 27 hemophilia B carriers, between 1987 and 2013, collected from the Swedish Medical Birth Register and the country’s National Patient Register. The control group consisted of 3,494 pregnancies.

The researchers looked at several maternal and neonatal characteristics, including the risk of bleeding after delivery or postpartum hemorrhage (PPH).

In Sweden, the more recent definition of PPH is blood loss of more than 1,000 mL following vaginal delivery or cesarean delivery. A previous guideline defined PPH as blood loss of more than 600 mL for vaginal births.

The study found that the risk of bleeding was more than three times higher in hemophilia B carriers than in non-carriers, but the risk for having other pregnancy complications, such as preeclampsia, was similar in all groups.

PPH occurred in 7.4% of the hemophilia A carriers, 21.6% of the hemophilia B carriers, and 6.6% of the control group.

“The lack of increase in FIX activity, in contrast to FVIII activity, during pregnancy is likely to have contributed to this main finding, since hemophilia carriers typically have prepregnancy FVIII and FIX activities at about 50% of those in non-carrier women,” the researchers wrote.

Moreover, according to the researchers, data from other studies in industrialized countries suggest that the prevalence of PPH is approximately 5%. However, “differing diagnostic criteria for PPH impede comparison between studies,” the authors wrote.

Of note, because PPH is commonly defined as blood loss of more than 500 mL following vaginal delivery, and of more than 1,000 mL following caesarean delivery, this study may actually underestimate the problem, the researchers said.

Additional results indicated that the incidence of pregnancy or neonatal complications was similar in carriers of hemophilia A or B compared with non-carriers. These complications included preeclampsia (3.0% in the hemophilia A group, 2.0% in the hemophilia B group, and 2.5% in the non-carrier group), preterm birth (gestational age of 32 to 37 weeks; 6.0%, 2.0%, and 5.4%), low birth weight (1,500 to 2,500 grams; 3.7%, 2.0%, and 3.2%) or low Apgar score (a measure of a newborn’s state of health; 1.0%, 0.0%, and 0.9%).

“This study suggests that there is an increased risk of PPH in unselected hemophilia B-carrier deliveries. The absence of increased FIX activity, but not FVIII activity, during pregnancy is likely to have influenced the results,” the researchers said.

Ana is a molecular biologist enthusiastic about innovation and communication. In her role as a science writer she wishes to bring the advances in medical science and technology closer to the public, particularly to those most in need of them. Ana holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she focused her research on molecular biology, epigenetics and infectious diseases.
Total Posts: 121
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
×
Ana is a molecular biologist enthusiastic about innovation and communication. In her role as a science writer she wishes to bring the advances in medical science and technology closer to the public, particularly to those most in need of them. Ana holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she focused her research on molecular biology, epigenetics and infectious diseases.
Latest Posts
  • coagulation test, hemophilia
  • postpartum bleeding, hemophilia
  • SB-525 ALTA trial
  • marstacimab, lab tests

Pin It on Pinterest

Share This